SCHEMBL6744329

SCHEMBL6744329

Cc1cc(OC(F)F)nc(S(C)(=O)=O)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
KMT2A Q03164 6/20 0.39
KDM4E B2RXH2 6/20 0.39
ALDH1A1 P00352 5/20 0.39
GAA P10253 2/20 0.34
RAB9A P51151 4/20 0.34
MEN1 O00255 3/20 0.34
TLR9 Q9NR96 3/20 0.34
AGTR1 P30556 1/20 0.34
SDHB P21912 4/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
MAPT P10636 3/20 0.32
HPGD P15428 5/20 0.31
NPSR1 Q6W5P4 5/20 0.31
STAT3 P40763 4/20 0.31
TP53 P04637 3/20 0.31
HTT P42858 3/20 0.31
HSD17B10 Q99714 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9329671 0.90 LMNA (0.60) LMNASMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL9432915 0.83 LMNA (0.73) LMNASMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL6561352 0.79 SMN1; SMN2 (0.78) LMNASMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL1051087 0.75 LMNA (0.52) LMNASMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL8869963 0.75 LMNA (0.50) LMNASMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL13012208 0.74 KMT2A (0.42) LMNASMN1; SMN2KMT2AALDH1A1GAA
SCHEMBL27836920 0.73 KMT2A (0.41) LMNASMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL9902644 0.73 LMNA (0.62) LMNASMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL8629598 0.72 CYP1A2 (0.50) SMN1; SMN2GAARAB9ACYP1A2CYP2C19
SCHEMBL9432361 0.72 ALDH1A1 (0.49) LMNASMN1; SMN2KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040023805-A1 Substituted phenyluracils ANDREE ROLAND (DE) 2004-02-05 US disclosed
US-6649760-B2 Herbicides BAYER AKTIENGESELLSCHAFT (DE) 2003-11-18 US disclosed
CN-1420873-A Substituted phenyluracils BAYER AG (DE) 2003-05-28 CN disclosed
EP-1272478-A1 SUBSTITUTED PHENYLURACILS Bayer Aktiengesellschaft (DE) 2003-01-08 EP disclosed
US-20020173425-A1 Substituted phenyluracils BAYER AKTIENGESELLSCHAFT (DE) 2002-11-21 US disclosed
WO-2001077084-A1 SUBSTITUTED PHENYLURACILS BAYER CROPSCIENCE AG (DE) 2001-10-18 WO disclosed
US-5284820-A Herbicidal substituted cycloalkenes BAYER AKTIENGESELLSCHAFT (DE) 1994-02-08 US disclosed
EP-0532948-A1 Substituted cycloalkenes as herbicides BAYER AG (DE) 1993-03-24 EP disclosed
EP-0158594-B1 PROCESS FOR THE PREPARATION OF FLUOROALKOXY-AMINO-PYRIMIDINES CIBA-GEIGY AG (CH) 1988-02-10 EP disclosed
EP-0158594-A1 Process for the preparation of fluoroalkoxy-amino-pyrimidines CIBA-GEIGY AG (CH) 1985-10-16 EP disclosed
US-4542216-A FLUOROALKYLATION OF A THIOPYRAMIDINE CIBA GEIGY CORPORATION (US) 1985-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173425-A1 Substituted phenyluracils DPYD, POP1, G6PD LMNA 4406/4885SMN1; SMN2 3026/4885KMT2A 1862/4885
US-20040023805-A1 Substituted phenyluracils DPYD, POP1, G6PD LMNA 4406/4885SMN1; SMN2 3026/4885KMT2A 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.